{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:51:12Z","timestamp":1787021472923,"version":"build-2736575974"},"reference-count":72,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["CDF-2014-07-037"],"award-info":[{"award-number":["CDF-2014-07-037"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NIHR Biomedical Research Centre based at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Patients with atopic dermatitis (AD) who do not adequately respond to topical therapy and phototherapy often need systemic immunomodulatory treatment to control their symptoms. Conventional systemic agents, such as ciclosporin, azathioprine, and methotrexate, have been used for decades, but there are concerns about their safety profile. There are now many novel systemic agents emerging through clinical trials, which may have great potential in the treatment of AD. Despite this, there are very few data comparing the performance of these drugs against each other. The purpose of this article is to review the current systemic therapies in AD and present an indirect comparison of systemic AD treatments using effectiveness and safety data from published randomised controlled trials, highlighting important remaining gaps in knowledge. Although the latest developments in systemic AD treatments are exciting and dearly needed, further work is required before the promise of a therapeutic revolution becomes reality.<\/ns4:p>","DOI":"10.12688\/f1000research.17039.1","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T05:15:05Z","timestamp":1548911705000},"page":"132","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0241-5408","authenticated-orcid":false,"given":"Helen","family":"Alexander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif K.","family":"Jabbar-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"e39803","DOI":"10.1371\/journal.pone.0039803","article-title":"Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.","volume":"7","author":"I Deckers","year":"2012","journal-title":"PLoS One."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"214-20","DOI":"10.1111\/all.13231","article-title":"Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide.","volume":"73","author":"J Thyssen","year":"2018","journal-title":"Allergy."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"525-32","DOI":"10.1016\/j.anai.2014.03.006","article-title":"Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention.","volume":"112","author":"N Garg","year":"2014","journal-title":"Ann Allergy Asthma Immunol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"e4770","DOI":"10.1136\/bmj.e4770","article-title":"Management of difficult and severe eczema in childhood.","volume":"345","author":"M McAleer","year":"2012","journal-title":"BMJ."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"774-774.e6","DOI":"10.1016\/j.jaci.2013.03.016","article-title":"Systemic therapies for severe atopic dermatitis in children and adults.","volume":"132","author":"C Flohr","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"S103-S105","DOI":"10.12788\/j.sder.2017.051","article-title":"Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution.","volume":"36","author":"L Eichenfield","year":"2017","journal-title":"Sem Cutan Med Surg."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"669-70","DOI":"10.20344\/amp.9787","article-title":"Atopic Dermatitis: The New Therapeutic Revolution in Dermatology.","volume":"30","author":"T Torres","year":"2017","journal-title":"Acta Med Port."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"S25-S27","DOI":"10.1016\/j.jaad.2017.12.025","article-title":"The future is finally here: Advances in the treatment of atopic dermatitis.","volume":"78","author":"M Zirwas","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"623-33","DOI":"10.1016\/j.jaad.2017.06.042","article-title":"When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.","volume":"77","author":"E Simpson","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"411-416.e4","DOI":"10.1016\/j.jaad.2018.09.053","article-title":"Relative efficacy of systemic treatments for atopic dermatitis.","volume":"80","author":"E Seger","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"281-5","DOI":"10.1016\/j.jaad.2016.09.021","article-title":"Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.","volume":"76","author":"C Totri","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"901-9","DOI":"10.1111\/bjd.12505","article-title":"The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey.","volume":"169","author":"L Proudfoot","year":"2013","journal-title":"Br J Dermatol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"1617-23","DOI":"10.1111\/bjd.15235","article-title":"Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists.","volume":"176","author":"K Taylor","year":"2017","journal-title":"Br J Dermatol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"1288-96","DOI":"10.1111\/bjd.16240","article-title":"Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial.","volume":"178","author":"L Gerbens","year":"2018","journal-title":"Br J Dermatol."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"710-1","DOI":"10.1111\/j.1365-2230.2008.02832.x","article-title":"Further experience of using azathioprine in the treatment of severe atopic dermatitis.","volume":"33","author":"R Hughes","year":"2008","journal-title":"Clin Exp Dermatol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"137-40","DOI":"10.1111\/j.1468-3083.1998.tb00766.x","article-title":"The use of azathioprine in severe adult atopic eczema.","volume":"11","author":"D Buckley","year":"1998","journal-title":"J Eur Acad Dermatol Venerol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"327-49","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.","volume":"71","author":"R Sidbury","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"429-38","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.","volume":"133","author":"E Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"1604-9","DOI":"10.1038\/ajg.2009.745","article-title":"Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study.","volume":"105","author":"R Armstrong","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1612-20","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.","volume":"141","author":"H Singh","year":"2011","journal-title":"Gastroenterology."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1617-25","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.","volume":"374","author":"L Beaugerie","year":"2009","journal-title":"Lancet."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1121-5","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.","volume":"54","author":"A Kandiel","year":"2005","journal-title":"Gut."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"2335-48","DOI":"10.1056\/NEJMoa1610020","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.","volume":"375","author":"E Simpson","year":"2016","journal-title":"N Engl J Med."},{"key":"ref-24","article-title":"Comparison of the efficacy of dupilumab versus cyclosporine using EASI thresholds in adult patients with moderate to severe atopic dermatitis","author":"L Ariens","year":"2018"},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"52-8","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy.","volume":"142","author":"J Harper","year":"2000","journal-title":"Br J Dermatol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"22-7","DOI":"10.1080\/00015550120235","article-title":"Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis.","volume":"81","author":"H Granlund","year":"2001","journal-title":"Acta Derm Venereol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"639-45","DOI":"10.1111\/j.1365-2222.2004.1907.x","article-title":"Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study.","volume":"34","author":"M Pacor","year":"2004","journal-title":"Clin Exp Allergy."},{"key":"ref-28","first-page":"139-43","article-title":"High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis.","volume":"4","author":"M Bemanian","year":"2005","journal-title":"Iran J Allergy Asthma Immunol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"661-8","DOI":"10.1111\/j.1365-2133.2009.09561.x","article-title":"Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial.","volume":"162","author":"J Schmitt","year":"2010","journal-title":"Br J Dermatol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"351-6","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt.","volume":"172","author":"M El-Khalawany","year":"2013","journal-title":"Eur J Pediatr."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fmed.2014.00033","article-title":"Cyclosporine and Extracorporeal Photopheresis are Equipotent in Treating Severe Atopic Dermatitis: A Randomized Cross-Over Study Comparing Two Efficient Treatment Modalities.","volume":"1","author":"U Koppelhus","year":"2014","journal-title":"Front Med (Lausanne)."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"44-51","DOI":"10.1111\/dth.12163","article-title":"Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial.","volume":"28","author":"S Jin","year":"2015","journal-title":"Dermatol Ther."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"120-5","DOI":"10.1111\/dth.12333","article-title":"Importance of concomitant topical therapy in moderate-to-severe atopic dermatitis treated with cyclosporine.","volume":"29","author":"J Kim","year":"2016","journal-title":"Dermatol Ther."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"562-569.e3","DOI":"10.1016\/j.jaip.2017.07.007","article-title":"Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial.","volume":"6","author":"C Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"324-30","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial.","volume":"147","author":"J Berth-Jones","year":"2002","journal-title":"Br J Dermatol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"839-46","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial.","volume":"367","author":"S Meggitt","year":"2006","journal-title":"Lancet."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"353-9","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema.","volume":"128","author":"M Schram","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"693-6","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.","volume":"60","author":"J Oldhoff","year":"2005","journal-title":"Allergy."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"89-93","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.","volume":"162","author":"S Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"130-9","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"371","author":"L Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"40-52","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial.","volume":"387","author":"D Tha\u00e7i","year":"2016","journal-title":"Lancet."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2287-2303","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"A Blauvelt","year":"2017","journal-title":"Lancet."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"1083-1101","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"M de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"28-35","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.","volume":"26","author":"S Khattri","year":"2017","journal-title":"Exp Dermatol."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"419-427","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: A randomized, double-blind, placebo-controlled, phase II study.","volume":"177","author":"H Saeki","year":"2017","journal-title":"Br J Dermatol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"826-835","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.","volume":"376","author":"T Ruzicka","year":"2017","journal-title":"N Engl J Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"1121-1130.e7","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.","volume":"142","author":"K Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"135-141","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.","volume":"143","author":"A Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"872-881.e6","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.","volume":"78","author":"E Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"ref-50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.","author":"E Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"863-871.e11","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).","volume":"78","author":"E Simpson","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1074-84","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial.","volume":"64","author":"I Haeck","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"489-509","DOI":"10.1007\/s40264-017-0636-9","article-title":"Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review.","volume":"41","author":"M Braddock","year":"2018","journal-title":"Drug Saf."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"686-90","DOI":"10.1016\/j.jaad.2006.09.011","article-title":"Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin.","volume":"56","author":"L Clarke","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"S69-71","DOI":"10.1016\/j.jaad.2005.09.015","article-title":"Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis.","volume":"57","author":"A Maruani","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1136\/annrheumdis-2018-eular.7079","article-title":"Malignancies and serious infections in randomised controlled trials of janus kinase inhibitors in patients with rheumatoid arthritis: a systematic review and meta-analysis.","volume":"77","author":"M Lopez-Olivo","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"3-4","DOI":"10.1016\/j.vhri.2013.02.012","article-title":"Future Prospects for Pharmacoeconomics and Outcomes Research in the Emerging Regions.","volume":"2","author":"M Drummond","year":"2013","journal-title":"Value Health Reg Issues."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"1081-102","DOI":"10.1215\/03616878-2373148","article-title":"Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?","volume":"38","author":"M Drummond","year":"2013","journal-title":"J Health Polit Policy Law."},{"key":"ref-59","first-page":"1-93","article-title":"Guide to the methods of technology appraisal 2013 [Internet].","year":"2013"},{"key":"ref-60","first-page":"1-76","article-title":"Guidelines for the economic evaluation of health technologies: Canada","author":"K Lee","year":"2017"},{"key":"ref-61","first-page":"1-205","article-title":"Health AGD of Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee","year":"2016"},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1095-108","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling Valuations for EuroQol Health States.","volume":"35","author":"P Dolan","year":"1997","journal-title":"Med Care."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"51-66","DOI":"10.1007\/s40273-017-0564-7","article-title":"The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal.","volume":"36","author":"E McManus","year":"2018","journal-title":"Pharmacoeconomics."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"113-125","DOI":"10.1007\/s40744-015-0020-0","article-title":"Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party.","volume":"2","author":"J Madan","year":"2015","journal-title":"Rheumatol Ther."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"677-87","DOI":"10.1002\/hec.1093","article-title":"Whither trial-based economic evaluation for health care decision making?","volume":"15","author":"M Sculpher","year":"2006","journal-title":"Health Econ."},{"key":"ref-66","article-title":"Dupilumab for treating moderate to severe atopic dermatitis","year":"2018"},{"key":"ref-67","article-title":"Dupilumab for treating moderate to severe atopic dermatitis [Internet]","year":"2018"},{"key":"ref-68","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16714","article-title":"TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.","author":"L Gerbens","year":"2018","journal-title":"Br J Dermatol."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"2014-2016","DOI":"10.1016\/j.jid.2017.05.014","article-title":"The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries.","volume":"137","author":"P Spuls","year":"2017","journal-title":"J Invest Dermatol."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"1297-1306","DOI":"10.1111\/bjd.16717","article-title":"A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: The TREatment of severe Atopic eczema Trial (TREAT).","volume":"179","author":"A Irvine","year":"2018","journal-title":"Br J Dermatol."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"800-7","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials.","volume":"134","author":"J Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA.","volume":"8","author":"A Chaimani","year":"2013","journal-title":"PLoS One."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/8-132\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-132\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/8-132\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T13:50:44Z","timestamp":1553867444000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/8-132\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":72,"URL":"https:\/\/doi.org\/10.12688\/f1000research.17039.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18628.r43434","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18628.r43435","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18628.r43433","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/8-132\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18628.r43433, Robert Sidbury, Dermatology Division, Seattle Children's Hospital, Seattle, USA, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-132\/v1#referee-response-43433","order":0,"name":"referee-response-43433","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18628.r43435, Gil Yosipovitch, Department of Dermatology and Cutaneous surgery and Itch Center, Miller School of Medicine, University of Miami, Miami, USA, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-132\/v1#referee-response-43435","order":1,"name":"referee-response-43435","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18628.r43434, Steven R Feldman, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, USA, 31 Jan 2019, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/8-132\/v1#referee-response-43434","order":2,"name":"referee-response-43434","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"CF is funded through a UK National Institute for Health Research (NIHR) Career Development Fellowship (CDF-2014-07-037). CF, HA, and ZKJ-L are supported by the NIHR Biomedical Research Centre based at Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}